- Patent Title: Pyridone derivative, composition and use as antiviral drug thereof
-
Application No.: US16487088Application Date: 2019-01-16
-
Publication No.: US11247993B2Publication Date: 2022-02-15
- Inventor: Li Chen , Qing Shao , Xiaojian Xue , Xiaowen Li
- Applicant: JIANGXI CAISHI PHARMACEUTICAL TECHNOLOGY CO., LTD.
- Applicant Address: CN Ganzhou
- Assignee: JIANGXI CAISHI PHARMACEUTICAL TECHNOLOGY CO., LTD.
- Current Assignee: JIANGXI CAISHI PHARMACEUTICAL TECHNOLOGY CO., LTD.
- Current Assignee Address: CN Ganzhou
- Agency: Venture Partner, LLC
- Agent Weisun Rao
- Priority: CN201810044308.4 20180117,CN201811517425.4 20181212
- International Application: PCT/CN2019/071902 WO 20190116
- International Announcement: WO2019/141179 WO 20190725
- Main IPC: C07D471/14
- IPC: C07D471/14 ; A61P31/16 ; C07D471/04 ; C07D498/14 ; C07D498/22 ; A61K45/06

Abstract:
The present disclosure belongs to the field of medicinal chemistry, and relates to a novel pyridone derivative represented by Formula (I) or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof, and use thereof in the preparation of a drug for preventing or treating diseases such as influenza type A viral infection and/or influenza type B viral infection, particularly use thereof as a PA subunit cap-dependent endonuclease inhibitor for preventing or treating diseases such as influenza type A viral infection and/or influenza type B viral infection. The compounds of the present disclosure have significant activity in inhibiting influenza endonuclease and influenza DNA, can be used either alone or in combination with a neuraminidase inhibitor, a nucleoside drug, a PB2 inhibitor, a PB1 inhibitor, an M2 inhibitor or other anti-influenza drugs, significantly shorten the time of influenza infection and reduces mortality, and have excellent clinical application prospects.
Information query